Sanofi, Regeneron Get Positive News from Drug Trials (SNY, REGN)

Photo of Paul Ausick
By Paul Ausick Updated Published

Invalid Image
An anti-cholesterol drug being co-developed by Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has shown positive results in two Phase II trials the companies reported this morning. The investigational drug, SAR236553/REGN727, reduced levels of LDL-C, or “bad,” cholesterol in 40%-72% of patients who were taking stable doses of statin drugs.

The drug could be important in helping patients reduce cholesterol levels further when they reach the limitations of what a statin drug can do, according to a press release.

The news has boosted Regeneron shares to a new 52-week high of $121.14, up more than 1%. Sanofy’s ADS are also up about 1% at $38.72.

Contact [email protected] for any questions or corrections.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Top Gaining Stocks

CRWD Vol: 11,962,734
GS Vol: 3,784,775
DELL Vol: 7,201,372
PANW Vol: 5,887,827
MPWR Vol: 777,369

Top Losing Stocks

IBM
IBM Vol: 67,107,622
CTRA Vol: 73,319,495
BIIB Vol: 3,821,509
HCA Vol: 4,227,228
ISRG Vol: 5,648,203